The Status Epilepticus drugs in development market research report provides comprehensive information on the therapeutics under development for Status Epilepticus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Status Epilepticus. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Status Epilepticus - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Status Epilepticus and features dormant and discontinued products.

GlobalData tracks 12 drugs in development for Status Epilepticus by 12 companies/universities/institutes. The top development phase for Status Epilepticus is preclinical with six drugs in that stage. The Status Epilepticus pipeline has 12 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Status Epilepticus pipeline products market are: Pfizer, Jazz Pharmaceuticals and Marinus Pharmaceuticals.

The key targets in the Status Epilepticus pipeline products market include Gamma-Aminobutyric Acid Type A Receptor Subunit (GABA(A) Receptor or GABR), G Protein Coupled Receptor 55 (GPR55), and Glutamate Ionotropic Receptor AMPA Type Subunit (AMPA Receptor or GRIA).

The key mechanisms of action in the Status Epilepticus pipeline product include Gamma-Aminobutyric Acid Type A Receptor Subunit (GABA(A) Receptor or GABR) Agonist with five drugs in Phase III. The Status Epilepticus pipeline products include seven routes of administration with the top ROA being Intravenous and two key molecule types in the Status Epilepticus pipeline products market including Small Molecule, and Antisense Oligonucleotide.

Status Epilepticus overview

Status epilepticus is an emergency neurological condition where seizures last for more than five minutes; historically, it was diagnosed for seizures longer than than 30 minutes. Patients with this condition do not regain consciousness between seizures, which can lead to death. Hence, it requires immediate emergency evaluation and management. Seizures can be convulsive or non-convulsive, and are most commonly observed in pediatric patients as febrile seizures. It can be caused by pre-existing seizures in patients on irregular medications, age, hypoxia, drug toxicity, genetics, head trauma, or CNS infections like meningitis. Neuroimaging studies and laboratory investigations are done for the diagnosis. CT scan, EEG, and MRI are the most common procedures. Management is primarily to abort the seizures by using emergency or rescue medications, providing supportive care with oxygen therapy, and anti-epileptic drugs.

For a complete picture of Status Epilepticus’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.